ABCC7 p.Ala462Cys

[switch to full view]
Comments [show]
Publications
PMID: 15623556 [PubMed] Berger AL et al: "Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain."
No. Sentence Comment
156 A462F reduced Po, as did treating A462C channels with NEM.
X
ABCC7 p.Ala462Cys 15623556:156:34
status: NEW
Login to comment

168 Fig. 5 shows that NEM treatment markedly reduced both A462C and A462C͞K464A current.
X
ABCC7 p.Ala462Cys 15623556:168:54
status: NEW
Login to comment

179 (A) Examples of recordings from CFTR-A462F, and of A462C channels before and after NEM treatment.
X
ABCC7 p.Ala462Cys 15623556:179:51
status: NEW
Login to comment

PMID: 17036051 [PubMed] Mense M et al: "In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer."
No. Sentence Comment
82 'NBD1` composite site, with A462C and S1347C, S459C and V1379C, and S434C and D1336C At the NBD1 composite site, we first examined crosslinking between positions homologous to those tested successfully at the NBD2 composite site.
X
ABCC7 p.Ala462Cys 17036051:82:28
status: NEW
Login to comment

86 Crosslinking was weaker, but still evident, 250 150 100 75 kDa - - - + + - + - + - - - + + - + - + - - - + + - + - + - - - + + - + - + - - - + + - + - + - - - + + - + - + fsk Anti-R-domainAnti-N-terminus BMOE BMH Background S434C S459C A462C S549C S605C - - - + + - + - + - - - + + - + - + - - - + + - + - + - - - + + - + - + - - - + + - + - + S1248C D1336C S1347C A1374C V1379C 250 150 100 75 50 Figure 5 The absence of efficient crosslinking when no, or only one, engineered cysteine is present.
X
ABCC7 p.Ala462Cys 17036051:86:236
status: NEW
Login to comment

101 250 160 105 75 50 Anti-R-domainAnti-N-terminus kDa fsk BMOE BMH - - + - + + + - + + - +- - - - + -- + + 0ЊC23ЊC X-link CFTR 1-633 1 2 3 4 5 6 7 8 + + - 23ЊC - - + - + + + - + + - +- - - - + -- + + 0ЊC23ЊC fsk BMOE BMH X-link CFTR 634-1480 9 10 11 12 13 14 + + - 15 16 23ЊC 0ЊC23ЊC 0ЊC23ЊC 0ЊC23ЊC 0ЊC23ЊC fsk BMOE BMH - - + - + + + - + + - +- - - - + -- + + X-link CFTR 1-633 1 2 3 4 5 6 7 fsk BMOE BMH X-link CFTR 634-1480 8 9 10 11 12 13 14 - - + - + + + - + + - +- - - - + -- + + 250 160 105 75 50 kDa fsk BMOE BMH - - + - + + + - + + - +- - - - + -- + + X-link CFTR 1-633 1 2 3 4 5 6 7 fsk BMOE BMH X-link CFTR 634-1480 8 9 10 11 12 13 14 - - + - + + + - + + - +- - - - + -- + + kDa 250 150 100 75 50 A B C (1-633) A462C and (634-1480) 9CS+S1347C (1-633) S459C and (634-1480) 9CS+V1379C (1-633) S434C and (634-1480) 9CS+D1336C Figure 8 Crosslinking across the 'NBD1` composite site.
X
ABCC7 p.Ala462Cys 17036051:101:803
status: NEW
Login to comment

104 (A) CFTR half channels (1-633) A462C (left panel) and (634-1480) 9CS þ S1347C (right panel).
X
ABCC7 p.Ala462Cys 17036051:104:31
status: NEW
Login to comment

187 Primers for cysteine insertions S434C, S459C, A462C, S549C, S605C, S1248C, D1336C, S1347C, A1374C and V1379C are given in Table I.
X
ABCC7 p.Ala462Cys 17036051:187:46
status: NEW
Login to comment

199 For recording macroscopic currents of split CFTR channels in excised patches (Figure 10), oocytes were Table I Forward primers for site-directed mutagenesis PCR C76S 50 -GCCCTTCGGCGATcgTTTTTCTGGAG-30 C276S 50 -CTGTTAAGGCCTACTcCTGGGAAGAAGC-30 C832S 50 -CGAAGAAGACCTTAAGGAGTcCTTTTTTGATGATATGGAGAGC-30 EagI site 50 -GGTAAAATTAAGCACAGcGGccGAATTTCATTCTGTTCTC-30 HA epitope 50 -CGGGCCGCCATGtAcccatAcGACGttccgGAttAcgcaAGGTCGCCTCTGG-30 CFTR 16CS C590A/C592A 50 -GGAGATCTTCGAGAGCgCTGTCgCTAAACTGATGGC-30 CFTR 16CS C590F/C592F 50 -GGAGATCTTCGAGAGCTtTGTCTtTAAACTGATGGC-30 CFTR 16CS C590L/C592L 50 -GGAGATCTTCGAGAGCctTGTCctTAAACTGATGGC-30 CFTR 16CS C590T/C592T 50 -GGAGATCTTCGAGAGCaCTGTCaCTAAACTGATGGC-30 CFTR 16CS C590V/C592V 50 -GGAGATCTTCGAGAGCgtcGTCgtTAAACTGATGGC-30 S434C 50 -CCTCTTCTTCAGTAATTTCTgtCTaCTTGGTACTCCTGTC-30 S459C 50 -GTTGGCGGTTGCTGGATgCACTGGAGCAGGCAAG-3 A462C 50 -GCTGGATCCACTGGGtgcGGCAAGACTTCACTTC-30 L549C 50 -GGTGGAATCACACtatGcGGAGGTCAACGAGCACG-30 S605C 50 -GGATTTTGGTCACaTgTAAAATGGAAC-30 S1248C 50 -CCTCTTGGGAAGAACCGGtTgtGGGAAGAGTAC-30 D1336C 50 -GTTTCCTGGGAAGCTTtgCTTTGTCCTTGTGG-30 L1346C 50 -GGATGGGGGCTCTGTCTgtAGTCATGGCCACAAGC-30 A1374C 50 -GATGAACCAAGCtgTCATTTAGATCC-30 V1379C 50 -GCTCATTTAGATCCgtgcACATACCAAATAATTCG-30 The underlined bases are the codons for the introduced serines, cysteines or other residues; lowercase letters mark base changes from the original sequence, including those for introducing diagnostic restriction endonuclease sites.
X
ABCC7 p.Ala462Cys 17036051:199:859
status: NEW
Login to comment

PMID: 9822656 [PubMed] Cotten JF et al: "Covalent modification of the nucleotide binding domains of cystic fibrosis transmembrane conductance regulator."
No. Sentence Comment
37 1 The abbreviations used are: CFTR, cystic fibrosis transmembrane conductance regulator; NEM, N-ethylmaleimide; PKA, catalytic subunit of cAMP-dependent protein kinase; ABC, ATP-binding cassette; NBD, nucleotide binding domain; NBD1-Cys, A462C/C832A; NBD2-Cys, C832A/S1248C; TB, mean burst duration; g, single channel conductance; ␶cs, slow, long closed time interval; ␶o, open time interval; ␶, time constant for rate of NEM modification; Iϱ, percentage of current remaining following complete NEM modification; TES, N-tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid.
X
ABCC7 p.Ala462Cys 9822656:37:238
status: NEW
Login to comment

73 NEM inhibits NBD1-Cys (CFTR-A462C/C832A) and NBD2-Cys(CFTR-S1248C/C832A) channel activity in an ATP-dependent manner. A, CFTR-C832A; B, CFTR-NBD1-Cys; C, CFTR-NBD2-Cys.
X
ABCC7 p.Ala462Cys 9822656:73:28
status: NEW
Login to comment